Relapsed; Refractory; Philadelphia Positive; B-precursor; Acute Lymphoblastic Leukemia; ALL; Blinatumomab; Leukemia;
Showing 1 - 25 of >10,000
Relapsed/Refractory Philadelphia Positive B-precursor ALL Trial in Worldwide (Blinatumomab)
Completed
- Relapsed/Refractory Philadelphia Positive B-precursor ALL
-
Duarte, California
- +21 more
Sep 8, 2022
B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)
Not yet recruiting
- B Precursor Acute Lymphoblastic Leukemia
- Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
- (no location specified)
Sep 25, 2023
B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- HY004
- +2 more
- (no location specified)
Aug 18, 2023
B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- (no location specified)
Oct 10, 2023
Acute Lymphoblastic Leukemia (ALL) Trial (Nilotinib)
No longer available
- Acute Lymphoblastic Leukemia (ALL)
- (no location specified)
Aug 5, 2022
Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia Trial in Japan (Blinatumomab)
Completed
- Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia
-
Nagoya-shi, Aichi, Japan
- +15 more
Dec 8, 2022
Next-generation Sequencing in Pediatric B-ALL Children Patients
Not yet recruiting
- Acute Lymphoblastic Leukemia, Pediatric
- (no location specified)
Apr 19, 2023
B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- QH103 Cell Injection
- +2 more
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Sep 21, 2023
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +7 more
- Blinatumomab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Acute Lymphoblastic Leukemia Trial (inotuzumab ozogamicin)
Not yet recruiting
- Acute Lymphoblastic Leukemia
- inotuzumab ozogamicin
- (no location specified)
Jan 6, 2023
B Acute Lymphoblastic Leukemia Trial in Suzhou (Blinatumomab)
Recruiting
- B Acute Lymphoblastic Leukemia
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University, Jiangsu Ins
Nov 1, 2022
Acute Lymphoblastic Leukemia Trial in Suzhou (cladribine, cytarabine,venetoclax)
Recruiting
- Acute Lymphoblastic Leukemia
- cladribine, cytarabine,venetoclax
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 22, 2022
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)
Not yet recruiting
- T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- CD7-CART01
- (no location specified)
Sep 26, 2023
Leukemia, Lymphoid Trial in Chengdu (blinatumomab)
Not yet recruiting
- Leukemia, Lymphoid
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
Oct 3, 2023
B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)
Recruiting
- B-Cell Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia
-
Tampa, FloridaMoffitt Cancer Center
Nov 28, 2023
ALL, Recurrent, Adult Trial in Frankfurt (Main), Kiel (Blinatumomab, Venetoclax)
Recruiting
- ALL, Recurrent, Adult
-
Frankfurt (Main), Hessen, Germany
- +1 more
Jan 6, 2022
B-cell Acute Lymphoblastic Leukemia Trial (single dose of CNCT19)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- single dose of CNCT19
- (no location specified)
Dec 19, 2022
Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive Trial in New York (Blinatumomab, dasatinib, dexamethasone)
Recruiting
- Acute Lymphoblastic Leukemia
- Philadelphia Chromosome-Positive
- Blinatumomab
- +3 more
-
New York, New York
- +1 more
Nov 10, 2022
CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL Trial in Suzhou (Treatment)
Recruiting
- CAR
- +2 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 27, 2022
B-cell Acute Lymphoblastic Leukemia Trial in Suzhou (Blinatumomab, Conventional therapy)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Blinatumomab
- Conventional therapy
-
Suzhou, Jiangsu, ChinaThe first affiliated hospital of Soochow University
Sep 26, 2022
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CD19 specific Chimeric Antigen Receptor T Cell
-
Columbus, OhioNationwide Children's Hospital
Mar 9, 2023
Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia Trial in Philadelphia (BEAM-201)
Recruiting
- Lymphoblastic Lymphoma
- +2 more
- BEAM-201
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jun 2, 2023
Refractory B-cell Acute Lymphoblastic Leukemia Trial in Houston (Mosunetuzumab)
Not yet recruiting
- Refractory B-cell Acute Lymphoblastic Leukemia
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2023
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Frankfurt (Imatinib, Ponatinib, Blinatumomab)
Recruiting
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Imatinib
- +3 more
-
Frankfurt, GermanyDepartment of Medicine, Hematology and Oncology, Goethe Universi
Sep 24, 2023
B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (U-CAR-T Cells (LstCAR019))
Withdrawn
- B-cell Acute Lymphoblastic Leukemia
- B-ALL
- U-CAR-T Cells (LstCAR019)
-
Kunming, Yunnan, ChinaKunming Hope of Health Hospital
Nov 27, 2022